FARALLON CAPITAL MANAGEMENT LLC - ARRAY BIOPHARMA INC ownership

ARRAY BIOPHARMA INC's ticker is ARRY and the CUSIP is 04269X105. A total of 324 filers reported holding ARRAY BIOPHARMA INC in Q2 2019. The put-call ratio across all filers is 1.86 and the average weighting 0.6%.

Quarter-by-quarter ownership
FARALLON CAPITAL MANAGEMENT LLC ownership history of ARRAY BIOPHARMA INC
ValueSharesWeighting
Q2 2019$393,805,000
+193.7%
8,500,000
+54.5%
2.56%
+154.1%
Q1 2019$134,090,000
+63.6%
5,500,000
-4.3%
1.01%
+67.7%
Q4 2018$81,938,000
+5.2%
5,750,000
+12.2%
0.60%
+30.7%
Q3 2018$77,900,000
-0.2%
5,125,000
+10.2%
0.46%
-4.6%
Q2 2018$78,027,000
+54.5%
4,650,000
+50.2%
0.48%
+37.7%
Q1 2018$50,510,0003,095,0000.35%
Other shareholders
ARRAY BIOPHARMA INC shareholders Q2 2019
NameSharesValueWeighting ↓
Redmile Group, LLC 16,618,776$146,079,00012.59%
BVF INC/IL 4,986,186$43,829,0008.81%
First Light Asset Management, LLC 1,000,361$8,793,0003.86%
Crosspoint Capital Strategies, LLC 463,005$4,070,0003.62%
Consonance Capital Management LP 2,723,471$23,912,0002.63%
KOPP INVESTMENT ADVISORS LLC 219,926$1,933,0002.04%
SPHERA FUNDS MANAGEMENT LTD. 900,000$7,911,0002.00%
Orbimed Advisors 16,088,800$141,421,0001.80%
Cormorant Asset Management, LP 1,150,000$10,109,0001.36%
BOGLE INVESTMENT MANAGEMENT L P /DE/ 2,073,680$18,227,0001.26%
View complete list of ARRAY BIOPHARMA INC shareholders